V' In six dogs anesthetized with halothane and nitrous oxide, mean arterial pressure (MAP) was lowered to 40 mm Hg for an average of 90 minutes by intravenous infusion of adenosine. The hypotensive effect of the adenosine was potentiated by administering dipyridamole to block its intravascular inactivation. Blood flow to the brain, spinal cord, heart, kidneys, and skeletal muscle was measured six times in each animal using the radioactive microsphere technique. Determinations were made before, during, and 30 minutes after the hypotensive period.
I
NDUCED arterial hypotension is commonly employed in neurosurgical practice to facilitate operations for aneurysms, arteriovenous malformations, and vascular tumors. 2, 1~ Furthermore, it is used in certain centers in an attempt to decrease the incidence of aneurysmal rebleeding in the preoperative period? ~ The most frequently used agents for inducing arterial hypotension include nitroprusside, nitroglycerin, trimethaphan, and halothane (intraoperatively). These agents all suffer from one or more of the following disadvantages: cyanide toxicity, rebound hypertension, decreased cardiac output, tachyphylaxis, and excessive cerebral vasodilation.S,1,- 13,3,,4o,42,46,57,6o Adenosine is a naturally occurring substance found ubiquitously in all body tissues. Given intravenously in pharmacological doses, it is a potent vasodilator in most vascular beds and readily produces profound reductions in arterial pressure. The purpose of this study was to document the cerebral and systemic vascular effects of parenterally administered adenosine in an attempt to determine its potential as a clinical agent for inducing arterial hypotension.
Materials and Methods
Six mongrel dogs, weighing approximately 15 kg each, were used for this study. The animals were anesthetized with 0.5% halothane in 70% nitrous oxide and 30% Oz. Muscular paralysis was achieved with pancuronium, 0.2 mg/kg given intravenously, supplemented as necessary. The animals were ventilated with a Harvard pump respirator,* and CO2 was added to the inspired gas mixture to maintain arterial pCO~ at 40 mm Hg. Temperature was measured from a Swan-Ganz thermistort and maintained at 37~ with a heating blanket.
Systemic arterial pressure was monitored from a catheter introduced into the aorta through the brachial artery. Sagittal sinus pressure was measured from a catheter placed in the anterior sagittal sinus and directed caudally into the posterior third of the sinus. Pulmonary artery wedge and central venous pressures, as well as cardiac output (using the thermodilution technique), were measured from a Swan-Ganz catheter inserted through the femoral vein. Left ventricle end diastolic pressure was measured using a pigtail catheter inserted retrogradely through the femoral artery. The position of the pigtail catheter in the left ventricle was confirmed by observing the waveform of the monitored pressure. Heart rate was derived from the electrocardiogram. End-tidal CO2 was measured continually with a Hewlett-Packard 47210A capnometer.:~ These physiological parameters were recorded continuously on a Hewlett-Packard 7758B eight-channel strip chart recorder.w Electroencephalograms (EEG's) were obtained from four needle electrodes placed in the scalp and recorded on a Grass Model 8-10 C electroencephalograph.l[ Blood flow to the brain and spinal cord, right and left ventricles of the heart, liver, kidney, stomach, jejunum, and temporalis and paraspinous muscles was measured using the radioactive microsphere technique. Regions of the central nervous system studied were the cortical gray matter, mixed white and gray matter samples from the right and left hemispheres, the corpus callosum, the right and left caudate nuclei, the brain stem, cerebellum, and the cervical and thoracic spinal cord. In each animal, six determinations of blood flow were made using 15 _+ 5 # carbonized spheres labeled with iodine-125, cerium-141, stannum-113, strontium-85, niobium-95, scandium-46, or gadolinium-153. The microspheres were injected into the left ventricle through the pigtail catheter. Femoral and brachial artery reference samples were drawn at a rate of 1.03 ml/min for 30 seconds before and 3 89 minutes after injection of the microspheres. The blood and tissue were counted in a Packard Auto-Gamma scintillation spectrometer. Immediately before each blood flow measurement, blood was drawn for determination of arterial blood gases, hematocrit, and oxygen content of arterial and cerebral venous (sagittal sinus) blood.
Cardiac index was estimated by dividing the cardiac output by the animal's weight. N. F. Kassell, et al by the stroke volume • 1.33 • 10 -3. Cerebral metabolic rate of oxygen usage (CMROz) was estimated by multiplying the difference between the arterial and sagittal sinus oxygen content by the mean cerebral hemisphere blood flow. Cerebral perfusion pressure was calculated as the difference between the mean arterial and sagittal sinus pressure. Cerebral vascular resistance was calculated by dividing the cerebral perfusion pressure by the total mean cerebral blood flow (CBF). Peripheral vascular resistance was calculated by dividing the difference between the mean arterial and central venous pressures by the cardiac index. Hypotension was induced by infusing a solution of adenosine, 0.4 gin/100 ml normal saline, at an average dose of approximately 3 mg/kg/hr. Dipyridamole, 1 mg/kg as a loading dose supplemented by 0.5 mg/kg every 30 minutes, was used to enhance the hypotensive effect of adenosine.
Blood flow and the other physiological and biochemical parameters were determined in the control state, 15 minutes after administration of the l-mg/ kg loading dose of dipyridamole ("dipyridamole period"), at approximately 30-minute intervals after blood pressure was lowered to a mean of 40 mm Hg ("hypotensive period") with a continuous infusion of adenosine supplemented with dipyridamole, 0.5 mg/ kg every 30 minutes and 30 minutes after discontinuation of the adenosine infusion ("recovery period"). The results are discussed in terms of the latter three periods: the dipyridamole, hypotensive, and recovery periods, and the changes are presented as a percentage of control values. The values for the hypotension period were obtained by averaging the three measurements taken at approximately 30-minute intervals during adenosine infusion. Statistical analysis of the data where necessary was performed using the pooled t-test. Differences were considered significant where p _< 0.05. Blood flow values are expressed in ml/100 gm/min.
Results

Dipyridamole Period
Administration of dipyridamole in a dose of I rag/ kg resulted in average reductions in mean arterial pressure (MAP) of 20% and peripheral vascular resistance of 32%. There was no significant change in heart rate or cardiac index, but stroke volume increased 20% (Table 1 and Fig. 1 ). Myocardial flow increased dramatically: 380% in the right ventricle and 73% in the left ventricle. Renal blood flow was not changed. Blood flow to the liver and stomach decreased 64% and 62%, while jejunum flow increased 26% (Table 2 and Fig. 2 ).
The CMROz did not change significantly. Cerebral vascular resistance decreased 27% while total brain blood flow remained unaffected (Table 3 and Figs. 3  and 4) . Cervical and thoracic cord flow did not change significantly (Table 4 ). There was no significant var- Values are mean • standard error of the mean. MAP = mean arterial pressure; CI = cardiac index: PVR = peripheral vascular resistance; SV = stroke volume; CW = cardiac work; SSP = sagittal sinus pressure; PAWP = pulmonary artery wedge pressure; LVEDP = left ventricle end diastolic pressure: PAP -pulmonary artery pressure; CVP = central venous pressure. Significance: ~ = p -0.05; 5; = P -< 0.0l; 9 = P <-0.001. iation in hematocrit, arterial blood gases, or acid-base balance ( Table 5) . The E E G was unchanged.
Hypotensive Period D u r i n g hypotension, p e r i p h e r a l vascular resistance was lowered by 61%, heart rate decreased by 33%, and cardiac index was r e d u c e d b y 14%. Stroke v o l u m e increased by 28% and cardiac w o r k decreased 59% (Table 1 and Fig. 1 ). Right ventricle b l o o d flow increased 271% and left ventricle flow 147%. K i d n e y blood flow decreased 70% and liver flow was decreased 87%, while stomach flow decreased 60% and j e j u n u m flow was increased 28% (Table 2 and Fig. 2 ).
The C M R O 2 did not change significantly. C e r e b r a l vascular resistance decreased 53% and total b r a i n flow decreased 28% (Table 3 and Fig. 4 ). The reduction in CBF was not homogeneous; flow decreased in the cerebral cortex by 31%, in the corpus callosum b y 38%, in the caudate by 29%, and in the c e r e b e l l u m by 22%. The b r a i n stem was essentially unaffected. Thoracic spinal cord flow decreased 26%, while the cervical cord flow increased 14% (Table 4 and Fig. 3 ).
Hematocrit and arterial pO2 and pCOz were unchanged, except for a slight elevation o f pCO2 at 60 minutes of hypotension. A significant metabolic acidosis developed, as d e m o n s t r a t e d by a reduction in arterial p H from a 7.33 +_ 0.01 control level to 7.25 _+ 0.01 in the recovery period, and a decrease in HCO3-from 17 +_ 1 to 14 +_ 1 at the same periods (Table 5) . D u r i n g the hypotensive period, the E E G showed no variation from the control state.
Recovery Period
Thirty minutes after discontinuation of the adenosine infusion, M A P h a d returned to the control level without rebound. C a r d i a c index, however, increased to a p p r o x i m a t e l y 127% of control, and peripheral vascular resistance r e m a i n e d a p p r o x i m a t e l y 27% be-F~G. 1. Cardiovascular parameters in six anesthetized dogs undergoing profound arterial hypotension induced by adenosine potentiated with dipyridamole. There is a very small drop in mean arterial pressure (MAP) and peripheral vascular resistance (PVR) with dipyridamole alone. The heart rate, MAP, cardiac work, and PVR are all reduced during the adenosine infusion, while cardiac index (C.I.) remained stable. LVEDP = left ventricular end diastolic pressure; SV = stroke volume; CVP = central venous pressure. *** = p < 0.001. low the initial value. Heart rate increased to just above the control value, while stroke volume and cardiac work were increased 22% and 23%, respectively (Table  1 and . J e j u n u m flow increased markedly, reaching 238% o f control (Table 2 a n d Fig. 2) .
The CMRO2 r e m a i n e d u n c h a n g e d from control values (Table 3 and Fig. 4 ). Total C B F increased from hypotensive levels but still r e m a i n e d 18% below control with p r o p o r t i o n a l increases in flow to the different regions o f the brain (Table 4 and Fig. 3 ). After the hypotensive period, there was a t e n d e n c y t o w a r d reversal o f the metabolic acidosis (Table 5) . Dipyridamole is a drug best k n o w n clinically for its anti-thrombotic effects. 139,26,43 However, it is also a vasodilator with particularly marked effects on the coronary circulation? ' 1~,4~ The vasodilatory properties of dipyridamole result principally from its ability to increase the circulating levels o f adenosine by inhibiting the m e m b r a n e -b o u n d active transport mechanism for adenosine in most tissues (particularly blood) and thus retard its inactivation. ~5,~ The circulatory effects of dipyridamole observed in this study were consistent with those reported elsewhere, 7 and will not be commented upon further. After administration o f dipyridamole, there was a reduction of approximately two orders o f magnitude in the dose of adenosine required to reduce M A P to 40 m m Hg. This enabled the desired level o f hypotension to be maintained with a minimal fluid load. Parenthetically, it should be noted that dogs are notoriously difficult animals in which to pharmacologically induce hypotension and we speculate that adenosine alone, without the potentiating effects of dipyridamole, m a y be sufficient to produce hypotension in higher primates and m a n without involving excessive volumes o f fluid.
Discussion
In this study, M A P was lowered approximately 60%, to 40 m m Hg. The reduction in M A P was mostly related to the decrease in peripheral vascular resistance, with only a small concomitant reduction in cardiac output. Hypotension resulted in a progressive metabolic acidosis which reversed upon restoration o f M A P to control levels. This metabolic acidosis presumably resulted from the decreased peripheral perfusion with an accumulation o f acid metabolites. The reduction in MAP of approximately 60% was associated with a disproportionate reduction in renal blood flow of approximately 70%. The kidney has an effective autoregulatory mechanism for preserving its blood flow in hypotensive situations. In a study of hypotension produced with trimethaphan, a 60% reduction in MAP to 40 mm Hg was associated with a fall in renal flow of only 31% (Kassell NF: unpublished data). However, adenosine has a vasoconstrictor effect on the kidney, in contrast to its vasodilator actions on most other organs. 23,3~,47,54,~9 Although renal blood flow increased after discontinuation of the adenosine infusion, it remained substantially below control levels. No explanation is available for this observation, although some residual effect of the dipyridamole may have been present when the recovery determination was made.
Liver blood flow demonstrated a gradual decline throughout the experiment. This is a nonspecific change seen with a variety of anesthetic agents and is not directly attributable to adenosine? ~ Stomach blood flow varied considerably, but the changes never reached statistical significance, while the jejunum showed little change until flow more than doubled during recovery. The reason for this change in blood flow to the jejunum is unclear.
Infusion of adenosine increased myocardial flow considerably, even though systemic arterial pressure was decreased. This was in part related to the direct coronary dilatory effect of adenosine, but was also probably due to the reduction in after-load demonstrated by a decrease in cardiac work of approximately 60%, while stroke volume increased approximately 30%. Heart rate decreased 30% and stayed down throughout the period of hypotension. This effect is probably a direct inhibitory action of adenosine on the conducting system of the heart. 4 Cerebral autoregulation appeared to be relatively intact in these animals. There was no change in total CBF after the 20% reduction in MAP from the loading dose of dipyridamole, and when MAP was lowered 61% with adenosine, CBF decreased only 28%. During hypotension, there was a marked reduction in cerebral vascular resistance. This was almost certainly on the basis of autoregulation rather than a direct effect of the adenosine since, as mentioned previously, adenosine has little effect on the cerebral circulation of dogs when it is delivered by the intravascular route. 24 The reduction in CBF was inhomogeneous with respect to the various regions of the brain. The cerebral cortex and corpus callosum were most affected, while the brain stern was least affected, Previous studies have documented the varying completeness of autoregulalion in different structures of the brain? 7 The mechanisms and implications of these observations are unknown.
Adenosine has a number of properties which suggest that it may be useful for inducing systemic arterial hypotension. In contrast to nitroprusside, nitroglycerin, trimethaphan, and hatothane, adenosine is a naturally occurring substance, In the doses employed in this study, adenosine appears to be nontoxic, In a separate study in our laboratory, 1 hour of adenosineinduced hypotension to an MAP of 40 mm Hg had no adverse effect on neurological, hematological, or biochemical parameters in dogs? ~ Adenosine is very rapidly inactivated in the circulation; hence the hypotension associated with its infusion is easily controlled and readily reversible. There is no tachyphylaxis during its administration and no rebound of arterial pressure above control levels following abrupt discontinuation. When administered by the intravenous route, adenosine probably does not dilate cerebral vessels or alter autoregulation. The fact that adenosine is not a primary cerebral vasodilator may be a distinct advantage in the neurosurgical environment. The degree of cerebral vasodilation associated with adenosine hypotension in this study is more or less in proportion to that required to sustain an adequate level of blood flow to the brain.
In summary, from a hemodynamic and pharmacological point of view, intravenous adenosine appears to have a variety of properties suggesting that it may be an effective clinical agent for inducing systemic arterial hypotension.
